IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0670051
(2000-09-25)
|
발명자
/ 주소 |
- Vacanti, Charles A.
- Cao, Yi Lin
- Langer, Robert S.
- Vacanti, Joseph P.
- Paige, Keith
- Upton, Joseph
|
출원인 / 주소 |
- Massachusetts Institute of Technology
- Children's Medical Center Corporation
|
대리인 / 주소 |
|
인용정보 |
피인용 횟수 :
55 인용 특허 :
94 |
초록
▼
Connective tissue, including neo-tendons and ligaments, has been constructed using biodegradable synthetic scaffolds seeded with tenocytes. The scaffolds are preferably formed from biodegradable fibers formed of a polymer such as polyglycolic acid-polylactic acid copolymers, and seeded with cells is
Connective tissue, including neo-tendons and ligaments, has been constructed using biodegradable synthetic scaffolds seeded with tenocytes. The scaffolds are preferably formed from biodegradable fibers formed of a polymer such as polyglycolic acid-polylactic acid copolymers, and seeded with cells isolated from autologous tendon or ligament by means of enzymatic digestion or direct seeding into tissue culture dishes from explants. The cell polymer constructs are then surgically transplanted to replace missing segments of functioning tendon or ligament.
대표청구항
▼
1. A connective tissue construct comprising:(a) a matrix suitable for implantation to form tendon or ligament consisting essentially of synthetic, biodegradable, biocompatible polymer fibers that have an interstitial spacing of between approximately 50 and 300 microns; and (b) dissociated connective
1. A connective tissue construct comprising:(a) a matrix suitable for implantation to form tendon or ligament consisting essentially of synthetic, biodegradable, biocompatible polymer fibers that have an interstitial spacing of between approximately 50 and 300 microns; and (b) dissociated connective tissue cells implanted in said matrix in an amount effective to form tendon or ligament following implantation into a patient in need thereof. 2. The construct of claim 1, wherein the cells are selected from the group consisting of tenocytes, ligamentum cells, fibroblasts, and chondrocytes.3. The construct of claim 1, wherein the polymer is selected from the group consisting of poly(lactide), poly(glycolic acid), poly(lactide-co-glycolide), poly(caprolactone), polycarbonates, polyamides, polyanhydrides, polyamino acids, polyorthoesters, polyacetals, degradable polycyanoacrylates, degradable polyurethanes, and polysaccharides.4. The construct of claim 1, wherein said matrix is suitable for implantation to form tendon.5. The construct of claim 1, wherein said matrix is suitable for implantation to form ligament.6. The construct of claim 1, wherein said polymer fibers are coated with compounds selected from basement membrane components, agar, agarose, gelatin, gum arabic, collagens types I, II, III, IV and V, fibronectin, laminin, glycosaminoglycans, polyvinyl alcohol, mixtures thereof, and other hydrophilic and peptide attachment materials.7. The construct of claim 6, wherein said polymer fibers are coated with polyvinyl alcohol or collagen.8. The construct of claim 1, wherein said construct further comprises a bioactive molecule.9. The construct of claim 8, wherein said bioactive molecule is selected from the group consisting of heparin binding growth factor, transforming growth factor alpha or beta, alpha fibroblastic growth factor, epidermal growth factor, vascular endothelium growth factor, nerve growth factor, muscle morphogenic factor, and steroidal anti-inflammatories.10. The construct of claim 8, wherein said bioactive molecule comprises 0.01-30% weight percentage of the construct.11. The construct of claim 10, wherein said bioactive molecule comprises 1-30% weight percentage of the construct.12. The construct of claim 2, wherein the cells are tenocytes or ligamentum cells.13. A connective tissue construct comprising:(a) a matrix suitable for implantation to form connective tissue consisting essentially of synthetic, biodegradable, biocompatible polymer fibers that have an interstitial spacing of between approximately 50 and 300 microns, wherein the polymer is selected from the group consisting of poly(caprolactone), polycarbonates, polyamides, polyamino acids, polyacetals, degradable polycyanoacrylates, degradable polyurethanes, and polysaccharides; and (b) dissociated connective tissue cells implanted in said matrix in an amount effective to form connective tissue following implantation into a patient in need thereof. 14. The construct of claim 13, wherein the cells are selected from the group consisting of tenocytes, ligamentum cells, fibroblasts, and chondrocytes.15. The construct of claim 13, wherein said construct is implanted to form new tendon.16. The construct of claim 13, wherein said construct is implanted to form new ligament.17. The construct of claim 13, wherein said polymer fibers are coated with compounds selected from basement membrane components, agar, agarose, gelatin, gum arabic, collagens types I, II, III, IV and V, fibronectin, laminin, glycosaminoglycans, polyvinyl alcohol, mixtures thereof, and other hydrophilic and peptide attachment materials.18. The construct of claim 17, wherein said polymer fibers are coated with polyvinyl alcohol or collagen.19. The construct of claim 13, wherein said construct further comprises a bioactive molecule.20. The construct of claim 19, wherein said bioactive molecule is selected from the group consisting of heparin binding growth factor, transforming growth factor alpha or beta, alpha fibroblastic growth factor, epidermal growth factor, vascular endothelium growth factor, nerve growth factor, muscle morphogenic factor, and steroidal anti-inflammatories.21. The construct of claim 19, wherein said bioactive molecule comprises 0.01-30% weight percentage of the construct.22. The construct of claim 21, wherein said bioactive molecule comprises 1-30% weight percentage of the construct.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.